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Abstract 
A mass spectrometry-based methodology has been developed for analysis of core-fucosylated 
versus antennary-fucosylated glycosites in glycoproteins. This procedure is applied to the 
glycoprotein alpha-1-antitrypsin (A1AT) which contains both core- and antennary-fucosylated 
glycosites. The workflow involves digestion of intact glycoproteins into glycopeptides, followed by 
double digestion with sialidase and galactosidase. The resulting glycopeptides with truncated glycans 
were separated using an off-line HILIC (Hydrophilic Interaction Liquid Chromatography) separation 
where multiple fractions were collected at various time intervals. The glycopeptides in each fraction 
were treated with PNGase F and then divided into halves. One half of the sample was applied for 
peptide identification while the other half was processed for glycan analysis by derivatizing with a 
Meladrazine reagent followed by mass spectrometry analysis. This procedure provided site-specific 
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fucosylation via a double digestion and a mass profile scan. Both core and antennary fucosylation 










Recent studies have shown that protein glycosylation can be related to disease states[1, 2]. In 
particular, fucosylation has been studied as a potential marker for several different cancers and 
diseases, such as hepatocellular carcinoma[3], pancreatic cancer[4] and lung cancer[5]. In some 
studies total fucosylation has often been shown to be related to disease state by using lectin blots[6-8]. 
However, more recently it has been found that specific fucosylation structures and the specific 
fucosylation sites of a glycoprotein may be more directly related to changes in disease[9, 10].  
The fucosylation structures include core fucosylation and antennary fucosylation where both may be 
present on any glycosylation site. One fucosylated glycoprotein usually has several fucosylation sites.  
Lectin blots can neither provide the fucosylation level of each site of the proteins nor distinguish the 
two fucosylation structures specifically. Some studies have used lectins to enrich the core-fucosylated 
or antennary-fucosylated glycoproteins before removing the glycan and analyze proteins and/or 
glycans separately[11, 12], where for example Aleuria Aurantia lectin (AAL) has high affinity to both 
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to core-fucosylated glycoproteins. However, such analyses missed the site-specific information and 
cannot provide direct evidence for core fucosylation or antennary fucosylation of these glycoproteins.  
Mass spectrometry (MS) can be used to identify most structures of glycans[13-15], but it is often 
difficult to do so for fucosylated glycans because the fucose glycosidic bond is labile in dissociation 
where even MS/MS may not distinguish whether it is core- or antennary-fucosylated. A widely 
accepted glycan structure analysis approach to distinguish the fucosylation structures uses various 
fucosidases to digest the glycan and analyze the glycan several times with HPLC (high pressure liquid 
chromatography), but this approach is very time consuming, which usually involves various 
fucosidases and several runs of HPLC analysis[5]. Recent studies have analyzed the glycopeptide 
with truncation of the glycan at the core glycan structure between GlcNAC-GlcNAC (N-
acetylglucosamine)[16, 17]. A core-fucosylated glycopeptide with core-fucose modification on the 
inner GlcNAC could be easily distinguished with mass spectrometry, where site-specific information 
was also maintained. However, this procedure cannot be applied to antennary fucosylation structures.  
In current work we have developed a methodology to distinguish core fucosylation and antennary 
fucosylation of glycans at each site of a glycoprotein as applied to the protein A1AT. The procedure 
involves a double digestion of glycopeptides with sialidase and galactosidase, followed by an off-line 
HILIC (Hydrophilic Interaction Liquid Chromatography) column separation of glycopeptides with a 
truncated glycan. Using this method only a single run of LC-MS analysis is needed for the 
sialidase/galactosidase digestion procedure to differentiate core/antennary fucosylation, whereas at 
least two runs are needed for the fucosidase digestion procedure, one run without fucosidase 
digestion and another run with corresponding fucosidase digestion. The glycopeptides in each 
fraction were further digested with PNGase F where the peptides are analyzed by LC-MS/MS (liquid 
chromatography with tandem mass spectrometry) directly and the glycans are derivatized by 
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glycosylation and to distinguish core fucosylation and antennary fucosylation via use of the mass 
profile scan in the protein A1AT. 
 
2 Materials and Methods 
2.1 Trypsin Digestion, Followed by Sialidase/Galactosidase Double Digestion: For trypsin digestion 
we added 10 µL of 100 mM triethylammonium bicarbonate (TEAB) to 30 µg alpha-1-antitrypsin 
(A1AT) and pipetted to dissolve the sample well. Then dissolved A1AT was reduced with 10 mM tris 
(2-carboxyethyl) phosphine (TCEP) at 37°C for 30 min and alkylated with 20 mM iodoacetamide (IAA) 
at room temperature in the dark for 15 min. The sample solution is diluted for 3 times with 100 mM 
TEAB and incubated with 2 µL (0.5 µg/µL) trypsin (Promega, Madison, WI) at 37°C for 16 h. The 
trypsin is eventually deactivated at 95°C for 5 min and dried in a speedvac. 
For the sialidase and galactosidase digestion, the glycopeptide mixture was dissolved in 30 µL of 25 
mM sodium acetate solution (pH5.5) and incubated with 15 mU (3 µL) of non-specific sialidase and 
75 mU (3 µL) of β(1-4,6) galactosidase (Prozyme, Hayward, CA) at 37°C for 18 h to remove all sialic 
acid residues and remove galactose on condition that no fucose is bound to the subterminal N-
acetylglucosamine in an N-glycan. The glycosidases were deactivated at 95°C for 5 min. In order to 
confirm core and antennary fucosylation of the sialidase/galactosidase double digested glycans, 
various fucosidases were used to cut the corresponding fucose as described by Varadi et al.[18].  
2.2 C18 Desalting: Trifluoroacetic acid (TFA) was added until the pH value reached 2. The columns 
were pre-wetted with 200 µL 0.1% TFA in 50% acetonitrile for 5 times and equilibrated with 0.1% 
TFA in water for 3 times by centrifugation at 1,500 g/min for 1 min each time. The peptides were 
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specific binding by centrifugation as described above; 20 µL of 50% acetonitrile with 0.1% TFA was 
used for elution by centrifugation as described above. Elution was repeated once and the combined 
eluents were then dried in a speedvac. 
2.3 Off-line HILIC Fractionation: The column used was a Waters Xbridge HILIC column, 2.1 mm × 150 
mm, 5 µm. The separations were performed on a Beckman HPLC system with detection at 214 nm. 
The sample was diluted to 100 µL with initial phase, and filtered with a 0.45 µm membrane. The 
gradient was set from 80% to 50% Solvent B (Solvent A: 10 mM ammonium formate; Solvent B: 980 
ml Acetonitrile, 20 ml H20, 0.1% formic acid) with a flow rate 0.2 ml/min and collection every 2 min. 
2.4 PNGase F digestion, Purification of Deglycosylated Peptides and Extraction of Glycan: N-
Glycosidase F (PNGase F, 2.5 U/10 µg protein) (New England Biolabs, Ipswich, MA) was added and 
incubated at 37°C for 18 h. PNGase F was deactivated by boiling for 5 min. Half of the protein glycan 
mixture was dried in a SpeedVac, desalted with a C18 column as described above and dried for 
further peptide identification by LC-MS. The other half was used for glycan structure analysis.  
10 µL porous graphitized carbon tips (PGC tips) (Sigma Aldrich, St. Louis, MO) were used to separate 
glycans from proteins and other impurities. The tip was activated by 50% ACN (with 0.1% TFA) and 
equilibrated with water (with 0.1% TFA). The samples were then loaded to the tip followed by 3 
washes with water (with 0.1% TFA) to remove nonspecific binding. Then 10 µL of 10% ACN (with 0.1% 
TFA) and 10 µL of 25% ACN (with 0.1% TFA) were used for glycan elution where the two eluents 
were combined and dried down for further glycan analysis. 
2.5 LC-MS Identification of Peptides: Nano LC-MS/MS conditions were as described in previous 
work[17]. A Magic C18 capillary column (100 μm × 15 cm; 3 μm particles, 200 Å) (Michrom 
Biosciences, Auburn, CA) was used for LC separation, and gradient elution was performed using a 




This article is protected by copyright. All rights reserved. 
 
nL/min. The mobile phase A was 2% acetonitrile with 0.1% formic acid in water and mobile phase B 
was 2% water with 0.1% formic acid in acetonitrile. The analytical gradient lasted for 80 min where 
the composition of solvent B rose from 5% to 32% in 50 min, followed by a washing and equilibration 
step where solvent B increased to 95% in 1 min and was held for 4 min, and then returned to 5% B in 
0.1 min and was held for 25 min.  
An ESI-LTQ mass spectrometer (Thermo Fisher Scientific, San Jose, CA) operated in positive ion mode 
was used for analysis. The ESI spray voltage and capillary voltage were set at 2.2 kV and 45 V 
respectively. Collision ionization dissociation (CID) fragmentation was performed at 35% of the 
normalized collision energy. The mass spectra were acquired in a data-dependent manner. Following 
a full scan in the mass range of m/z 400 to 1800, CID MS/MS was performed on the five most intense 
ions. 
2.6 Database Search for Peptide Identification: The mass spectrum was searched with Proteome 
Discoverer1.2 (Thermo Fisher Scientific, San Jose, CA) software with SEQUEST using the following 
settings: (1) fixed modification: cysteine carbamidomethylation (+57.0 Da); (2) Dynamic modification: 
methionine oxidation (+16.0 Da), addition of +1 Da to Asparagine residue due to PNGase digestion; 
(3) One missed cleavage was allowed; (4) Peptide ion tolerance: 1.4 Da; (5) Fragment ion tolerance: 
0.8 Da; (6) SWISS-PROT Homo sapiens database (reviewed, downloaded in April 2014) was used. 
2.7 Glycan Derivatization with Meladrazine:  For derivatization of the glycans by Meladrazine[19, 
20], the glycans were dissolved in 1 µL H2O and then 20 µL Meladrazine (T3) labeling reagent (Mr 
235.2115) was added (50 mM, methanol: acetic acid=3:1) at 60°C for 3 hours. For LC analysis, the 
samples were then dried and dissolved in 20 µL 80% ACN for HILIC separation.  
2.8 LC-MS Identification for Derivatized Glycans: LC−MS system used for glycan identification was 
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nano column. A HALO Penta-HILIC column (2.1 mm × 150 mm, 5 μm particle size) was used. Mobile 
phases A and B were 10 mM ammonium formate in water (pH 6.5) and 98% ACN containing 0.1% 
formic acid, respectively. Ten microliters of sample was injected at the initial gradient condition (80% 
mobile phase). The gradient was then ramped from 80 to 50% solvent B over 25 min with a total run 
time of 40 min. Glycans were eluted at 0.2 mL/min. The positive ion mode was used for analysis. The 
MS detection range was set at 800 to 2000 m/z. The ESI spray and capillary voltages were set at 5 kV 
and 35 V, respectively, with the stainless steel capillary heating to 275°C. The glycan structures were 
further confirmed by CID MS/MS using the LTQ Orbitrap Velos. Precursor ions were selected in data 
dependent acquisition (DDA) mode. The glycans were permethylated prior to MS/MS analysis for 
better ionization of the fragments and preventing glycan rearrangement in the gas phase. In order to 
isomerically separate permethylated glycans, a porous graphitic carbon (PGC) column (HyperCarb, 
10 μm × 100 mm, 5 μm particle size) was utilized in LC-MS/MS analysis. 
2.9 Data Analysis of Glycans: Theoretical structures and m/z values of derivatized glycans were 
generated by GlycoWorkbench Software developed by the EUROCarbDB. The experimental value 
was used to confirm the results. The identified glycans were quantified manually with Xcalibur Qual 
Browser 2.1 (Thermo Fisher Scientific, San Jose, CA) using the peak area from the extracted ion 
chromatogram (XIC) with the following settings: (1) peaks were extracted with a 1 Da ( ±0.5 Da) mass 
window, (2) scan filter was set as full MS, and (3) Genesis peak detection algorithm was used. 
Nomenclature of glycan is used according to Essentials of Glycobiology[21] and the abbreviations are 
used according to NIBRT GlycoBase. 
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There are two different types of fucosylation structures of N-linked glycoprotein, which have been of 
interest in biomarker studies, i.e. core fucosylation and antennary fucosylation. It is often difficult to 
distinguish the two structures using direct ESI-MS/MS due to the low fragmentation signals in 
MS/MS analysis for glycans. The glycosylation is also known to be site-specific[16, 22]. We thus 
sought to develop a method to analyze site specific fucosylation of a model protein A1AT (alpha-1-
antitrypsin) to distinguish core fucosylation and antennary fucosylation structures at each glycosite. A 
work-flow describing the methods used is shown in Figure 1. 
Sialidase releases α(2-3,6,8,9)-linked N-acetylneuraminic acid leaving galactose as the terminal of the 
N-glycan. Subsequently, β-galactosidase cleaves β(1-4,6)-linked galactose on condition that no fucose 
is bound to the  subterminal N-acetylglucosamine in an N-glycan, thus providing a means to 
distinguish core fucosylation and antennary fucosylation (as illustrated in Figure 2). The elongation 
of polylactosamine-type structure is not considered in this study. A previous study about the glycan 
structures of A1AT has shown that no polylactosamine-type structure has been found in human 
serum[23]. In our analysis, no obvious polylactosamine-type structure was detected. A list of sialidase 
or sialidase/galactosidase digested N-glycans are shown in Table 1 and the theoretical m/z is 
calculated using GlycoWorkbench. In order to further enhance the ionization efficiency of glycans for 
detection, a Meladrazine derivatization reagent was used. In the Thermo LTQ ion trap instrument, the 
signal in the m/z range of 1000-2000 is more intense than the lower or the higher mass ranges. The 
m/z within this range is indicated in bold. As shown in Table 1 the core-fucosylated glycan and the 
antennary-fucosylated glycan have the same m/z in sialidase digested sample while the two have 
different m/z in the sialidase/galactosidase double digested sample. Therefore with 
sialidase/galactosidase double digestion the two types of fucosylation are readily distinguished 
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Further MS/MS analysis and fucosidase digestion analysis were also performed to confirm this result. 
The MS/MS data are shown in the supporting information. The MS/MS spectra of core-fucosylated 
and antennary-fucosylated bi-antennary and tri-antennary glycans are shown in the supporting 
information Figure S1. It could be clearly seen that galactosidase was not able to cut the galactose 
off if an antennary-fucosylation was formed, leaving both galactose and fucose on the glycan; 
whereas the fucosylation that formed at the core position does not have galactose left after 
galactosidase digestion. At the same time, this was also confirmed by fucosidase digestion analysis. 
The XIC of tri-antennary glycans, either core-fucosylated or antennary-fucosylated were extracted 
after various fucosidase digestions, as shown in the supporting information Figure S2. After core 
fucosidase α1-2,3,4,6 fucosidase digestion (which cuts core fucosylation more efficiently than 
antennary fucosylation), the peak of core-fucosylated tri-antennary glycan(FA3) fully disappeared 
and some of the antennary-fucosylated tri-antennary glycan (A3FG) also disappeared with the 
appearance of its product glycan (A3G). After antennary fucosidase (α1-2 fucosidase and α1-3,4 
fucosidase) digestion, the peak of FA3 did not change whereas most of A3FG disappeared with the 
appearance of A3G. This result confirmed the results from our method.  
In this study A1AT was used as the model protein. The tri-antennary glycan of A1AT was used as an 
example as shown in Figure 3. Two aliquots of 10 µg A1AT were digested with a single sialidase or 
with sialidase/galactosidase double digestion in parallel for comparison. The base peak of the 
theoretical m/z of a glycan was extracted manually using Xcalibur. With a single sialidase digestion, 
one peak with m/z 1203.49 (FA3G3 or A3FG3, the abbreviations of glycan structure are used 
according to NIBRT GlycoBase) was found, indicating there is one fucose attached to the tri-antennary 
glycan, but it is unknown whether it is core fucosylation or antennary fucosylation. With 
sialidase/galactosidase, the peak with m/z 1203.49 disappeared, and a minor peak with m/z 1901.83 
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core-fucosylated tri-antennary glycan at lower abundance and an antennary-fucosylated tri-antennary 
glycan at higher abundance. The completeness of galactosidase digestion is verified by extracting the  
XIC of the half-digested glycan structure with m/z at 1113.48 (FA3G2 or A3FG2). It can be seen 
clearly that there is no half-digested glycan structure so that galactosidase digestion is complete.  
Analysis of A1AT showed that there are 12 different glycan structures after sialidase/galactosidase 
double digestion as shown in Table 2. The retention time of a core-fucosylated glycan is around 30 s 
longer than its corresponding non-fucosylated glycan; while the antennary-fucosylated glycan is 
around 100 s longer than its corresponding non-fucosylated glycan, indicating that the addition of one 
core-fucose enhanced the hydrophilicity of the glycopeptides and the addition of an antennary-fucose 
and a galactose enhanced its hydrophilicity further. The nonfucosylated biantennary and tri-antennary 
glycans are the top two most abundant glycan structures of A1AT, comprising 35.8% and 25.2% 
respectively. Both core and antennary fucosylation were found, with overall antennary fucosylation 
levels much higher than core fucosylation levels. In a classical lectin blot assay, one study has found 
that the up-regulation of core-fucosylated but not antennary-fucosylated A1AT could be indicative for 
hepatocellular cancer diagnosis [9]. The procedure developed in this study would enable the precise 
identification and quantification of core and antennary fucosylation of A1AT.   
It is not known yet which site has core fucosylation or antennary fucosylation and the relative amount 
of the two fucosylations at each glycosite. A1AT has three theoretical N-glycosylation sites, all of 
which are detectable with trypsin digestion: site 70, site 107 and site 271. In order to determine the 
site specificity and the fucosylation type of each site, A1AT was first digested with trypsin, followed 
by sialidase/galactosidase double digestion. The A1AT glycopeptide mixture was then fractionated 
with a HILIC column into 30 fractions prior to PNGase F digestion. Each fraction was divided into 
two equal parts. One set of all the fractions was used for peptide identification, and the other set was 
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was quantified by #PSMs (the number of peptide spectrum matches) from ProteomeDiscoverer1.2 
search engine. With PNGase F digestion, previously glycosylated peptides are deamidated showing 
+1 Da dynamic modification at the site of asparagines whereas the nonglycosylated peptides do not 
have this modification. The aim of HILIC separation is to separate different peptides rather than a 
quantitative comparison of glycosylated and non-glycosylated peptides. Considering the chemical 
deamidation rate is less than 7%[25], where our experiment showed that the amount of deamidated 
peptides was about twice the amount of non-deamidated peptides, chemical deamidation was not 
specifically differentiated with glycosylated peptides. Most of these deamidated peptides in the 
fraction were from glycosylated peptides rather than chemical deamidation. 
All fractions have been checked by LC-MS/MS. The result showed that the glycopeptides with 
truncated glycans were found in the same fraction as non-glycopeptides, where the fraction was 
collected at every 2 min (Figure 4).  The non-glycosylated peptides may not elute at the same 
retention time as glycosylated peptides but the two eluted at similar retention time and in the same 
fraction with the Xbridge HILIC column in our experimental system.  Therefore, the glycan structures 
of one site can be identified in sequential fractions. Three fractions F17 (fraction 17), F20 and F26 
have maximum #PSMs of three glycopeptides of A1AT. As shown in Table 3, F17 mainly contains the 
glycopeptide YLGnATAIFFLPDEGK with site 271; F20 mainly contains the glycopeptide 
ADTHDEILEGLNFnLTEIPEAQIHEGFQELLR with site 107; F26 mainly contains the glycopeptide 
QLAHQSnSTNIFFSPVSIATAFAMLSLGTK with site 70. The MS/MS spectrum of one of the identified 
peptides of A1AT with glycosylation site 271, YLGnATAIFFLPDEGK (The deamidated asparagine is 
indicated by lower case) is shown in supporting information Figure S3. The glycan structures of the 
three fractions were further analyzed with LC-MS. The glycan was first extracted by PGC tips 
following PNGase F digestion and derivatized with T3 labeling reagent. Three glycan structures were 
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including A2, A3, A4, A3FG, A4FG (Figure 5B); No glycans were identified in F26, where within the 
limits of our current experiments no glycans were observed for site 70. The mass spectra of glycans 
are shown in supporting information Figure S4.  
 
4 Concluding Remarks  
We have developed a work-flow to study the glycosylation of A1AT to identify the presence of core 
versus antennary fucosylation. This was performed on a standard A1AT protein which was digested 
by trypsin followed by sialidase/galactosidase digestion. Galactosidase removes terminal galactose 
residues in an N-glycan but does not cut when the subterminal N-acetylglucosamine is modified by 
fucosylation, thus providing a means to distinguish core fucosylation and antennary fucosylation. 
The resulting peptides were separated by HILIC separation and collected into 30 fractions. For each 
fraction the glycans were released using PNGase F digestion. The glycans could then be extracted 
and analyzed using Meladrazine T3 labeling reagent and HILIC-LC/MS where glycans with core or 
antennary fucosylation could be identified via mass spectrometry. In addition, the site of 
glycosylation could be studied via C18 extraction of the peptides followed by LC-MS/MS analysis. We 
identified 12 different glycans at two different glycosites in A1AT following sialidase/galactosidase 
digestion which clearly showed the presence of core versus antennary fucosylation. In future work, 
this methodology will be used to study changes in serum A1AT glycosylation during the progression 
of various cancers. 
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Table 1.  The list of sialidase or sialidase/galactosidase digested N-glycans and their theoretical m/z. 
The m/z within 1000-2000 mass range is indicated in bold.  
Glycan Type 
Digest with Sialidase Digest with Sialidase/Galactosidase 
[M-T3+H]
+
































































blue square, GlcNAc; green circle, mannose; yellow circle, galactose; red triangle, fucose  
Table 2. Summary of truncated N-glycans identified in A1AT, including m/z, retention time and % 








A2 1552.7 7.72 35.8% 
FA2 1698.8 8.37 1.8% 
A2FG 1860.8 9.66 0.5% 
A3 1755.8 8.43 25.2% 
FA3 1901.8 8.99 0.7% 
A3FG 1041.5 10.2 11.3% 
A4 1958.8 9.24 7.0% 
A4FG 1142.9 10.92 13.6% 
A3F2G2 1195.5 11.74 0.4% 
FA3FG 1114.5 10.69 0.1% 
A4F2G2 1297.0 12.05 3.6% 














Table 3. The peptide identified in fractions of HILIC column fractionation. The glycosylation site is 
indicated by lower case.  
Fraction No. Site Peptide 
F26 site 70 QLAHQSnSTNIFFSPVSIATAFAMLSLGTK 
F20 site 107 ADTHDEILEGLNFnLTEIPEAQIHEGFQELLR 






















Figure Captions  
Figure 1. Work-flow of the experiment for determining glycosylation of A1AT. The glycosylated A1AT 
was first digested into peptides, followed by glycan truncation by sialidase/galactosidase double 
digestion. The glycopeptides were fractionated using a HILIC column. PNGase F digestion was used 
for separate mass spectral analysis of glycans and peptides. 
Figure 2. Schematic of digestion by galactosidase which illustrates that digestion occurs for core 
fucosylation but not antennary fucosylation.  
Figure 3.  The fucosylation structure of fucosylated tri-antennary glycan treated by sialidase 
digestion (A) cannot be distinguished, whereas with sialidase/galactosidase double digestion (B) the 
core-fucosylated tri-antennary glycan with m/z at 1901.83 (FA3) elutes earlier than antennary-
fucosylated tri-antennary glycan with m/z at 1041.45 (A3FG). The completeness of galactosidase 
digestion is verified by extracting the XIC of  the half-digested glycan structure with m/z at 1113.48 
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Figure 4. The #PSMs of identified glycosylated peptides or non-glycosylated peptides in fractions of 
HILIC fractionation. Deamidated peptides after PNGase digestion are considered glycosylated 
peptides, whereas non-glycosylated peptides are not deamidated. Chemical deamidated peptides 
were not differentiated due to their low percentile. “site70_deamidated” “site107_deamidated” and 
“site 271_deamidated”indicate glycosylated peptides with glycosylation site 70, 107 and 271 
respectively “site 70” “site 107” and “site 271” indicate the corresponding non-glycosylated peptides.  
Figure 5. LC-MS analysis of glycans in F17 (A) and F20 (B) from HILIC column fractionation. F17 
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